• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

    1.820 -0.020 (-1.09%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 237,903
    Open 1.840
    Bid (Size) 1.830 (1,400)
    Ask (Size) 1.900 (2,500)
    Prev. Close 1.840
    Today's Range 1.820 - 1.953
    52wk Range 0.6101 - 4.220
    Shares Outstanding 54,808,715
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
    Issued on behalf of Oncolytics Biotech Inc. 
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire

    Performance

    YTD
    -33.3%
    -33.3%
    1 Month
    -19.5%
    -19.5%
    3 Month
    +15.2%
    +15.2%
    6 Month
    +100.0%
    +100.0%
    1 Year
    +49.2%
    +49.2%

    More News

    Read More
    News headline image
    PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
    Via FinancialNewsMedia
    News headline image
    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
    From FN Media Group LLC
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
    Via Benzinga
    News headline image
    Prelude Therapeutics Inc. (NASDAQ:PRLD) Beats Q3 2025 Earnings Estimates and Extends Cash Runway ↗
    Via Chartmill
    News headline image
    Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    In today's session, these stocks are experiencing unusual volume. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Which stocks are experiencing notable movement on Tuesday? ↗
    Via Chartmill
    News headline image
    On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
    Via Chartmill
    News headline image
    Tuesday's session: top gainers and losers ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    News headline image
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Dow Dips Over 400 Points; Pfizer Earnings Top Estimates ↗
    Via Benzinga
    Topics Stocks
    News headline image
    Tuesday's pre-market session: top gainers and losers ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Prelude Therapeutics Announces Strategic Business Update
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    These stocks are moving in today's after hours session ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    News headline image
    Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire

    Frequently Asked Questions

    Is Prelude Therapeutics Incorporated - Common Stock publicly traded?
    Yes, Prelude Therapeutics Incorporated - Common Stock is publicly traded.
    What exchange does Prelude Therapeutics Incorporated - Common Stock trade on?
    Prelude Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Prelude Therapeutics Incorporated - Common Stock?
    The ticker symbol for Prelude Therapeutics Incorporated - Common Stock is PRLD on the Nasdaq Stock Market
    What is the current price of Prelude Therapeutics Incorporated - Common Stock?
    The current price of Prelude Therapeutics Incorporated - Common Stock is 1.820
    When was Prelude Therapeutics Incorporated - Common Stock last traded?
    The last trade of Prelude Therapeutics Incorporated - Common Stock was at 01/21/26 04:00 PM ET
    What is the market capitalization of Prelude Therapeutics Incorporated - Common Stock?
    The market capitalization of Prelude Therapeutics Incorporated - Common Stock is 99.75M
    How many shares of Prelude Therapeutics Incorporated - Common Stock are outstanding?
    Prelude Therapeutics Incorporated - Common Stock has 100M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.